NBRV - Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China

Nabriva Therapeutics (NBRV) announces restructuring its license agreement for community acquired bacterial pneumonia treatment Xenleta in the greater China region. Sinovant Sciences will now provide additional manufacturing and regulatory support.The amendment accelerates components of a $5M milestone payment to Nabriva that was previously payable upon the treatment's regulatory approval in China, including a $1M payment in Q4.Nabriva is also eligible for approximately $90M in additional payments tied to certain regulatory and commercial milestones for Xenleta in China. The company will also receive low double-digit royalties on sales.Sinovant Sciences is currently concluding its Xenleta clinical trial in China.Nabriva shares are up 4% pre-market to $3.85.Previously: Nabriva Therapeutics secures new reimbursement for Xenleta and Contepo (Sep. 10 2020)

For further details see:

Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China